Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-03-29
2011-03-29
Li, Bao (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S232100, C424S093100, C435S005000
Reexamination Certificate
active
07914788
ABSTRACT:
The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
REFERENCES:
patent: WO 2003/068151 (2003-08-01), None
patent: WO 2005/013918 (2005-02-01), None
Carayannopolous et al. In Fundamental Immunology, edited by William E. Paull, 3rd Edition, 1993, pp. 283-314.
Rudikoff et al. Proc. Natl. Acad. Sci. USA 1982 vol. 79: p. 1979.
Aldaz-Carroll et al. J. Virol. 2005, vol. 79, No. 10, pp. 6260-6271.
Aldaz-Carroll et al., “Epitope-Mapping Studies Define Two Major Neutralization Sites on the Vaccinia Virus Extracellular Enveloped Virus Glycoprotein B5 R,”J Virol, vol. 79, pp. 6260-6271, 2005.
Bell et al, “Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin,”Virology(Academic Press, Orlando), vol. 325, No. 2, pp. 425-431, Aug. 1, 2004.
Blasco et al., “Role of Cell-Associated Enveloped Vaccinia Virus in Cell-to-Cell Spread,”J Virol, vol. 66, pp. 4170-4179, 1992.
Blasco et al., “Dissociation of Progeny Vaccinia Virus from the Cell Membrane is Regulated by a Viral Envelope Glycoprotein: Effect of a Point Mutation in the Lectin Homology Domain of the A34R Gene,”J Virol, vol. 67, pp. 3319-3325, 1993.
Chen et al., “Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus,” Proceedings of the National Academy of Sciences of USE, National Academy of Science, Washington, DC, US, vol. 103, No. 6, pp. 1882-1887, Feb. 7, 2006.
Englestad et al., “A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope,”Virology, vol. 188, pp. 801-810, 1992.
Englestad and Smith, “The Vaccinia Virus 42-kDa Envelope Protein Is Required for the Envelopment and Egress of Extracellular Virus and for Virus Virulence,”Virology, vol. 194, pp. 627-637, 1993.
Erlich, et al., “Potential of primate monoclonal antibodies to substitute for human antibodies: nucleotide sequence of chimpanzee Fab fragments,”Hum Antibodies Hybridomas, vol. 1, pp. 23-26, 1990.
Feery, “The efficacy of vaccinial immune globulin. A 15-year study,”Vox Sang, vol. 31, pp. 68-76, 1976.
Fulginiti et al, “Smallpox Vaccination: A Review, Part II. Adverse Events,”Clin Infect Dis, vol. 37, pp. 251-271, 2003.
Galmiche et al., “Neutralizing and Protective Antibodies Directed against Vaccinia Virus Envelope Antigens ,”Virology, vol. 254, pp. 71-80, 1999.
Henderson, “The Looming Threat of Bioterrorism,”Science, vol. 283, pp. 1279-1282, 1999.
Hopkins et al, “Safety and Pharmacokinetic Evaluation of Intravenous Vaccinia Immune Globulin in Healthy Volunteers,”Clin Infect Dis, vol. 39, pp. 759-766, 2004.
Hopkins et al, “Clinical Efficacy of Intramuscular Vaccinia Immune Globulin: A Literature Review,”Clin Infect Dis, vol. 39, pp. 819-826, 2004.
Isaacs et al., “Characterization of a Vaccinia Virus-Encoded 42-Kilodalton Class I Membrane Glycoprotein Component of the Extracellular Virus Envelope,”J Virol, vol. 66, pp. 7217-7224, 1992.
Kempe, “Studies on Smallpox and Complications of Smallpox Vaccination,”Pediatrics, vol. 26, pp. 176-189, 1960.
Law et al, “Antibody Neutralization of the Extracellular Enveloped Form of Vaccinia Virus,”Virology, vol. 280, pp. 132-142, 2001.
Lustig et al, “Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge,”Journal of Virology, vol. 79, No. 21, pp. 13454-13462, Nov. 2005.
Men Ruhe et al, “Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus,”Journal of Virology, vol. 78, No. 9, pp. 4665-4674, May 2004.
Moss, “Poxvirus entry and membrane fusion ,”Virology, vol. 344, pp. 48-54, 2005.
Payne, “Significance of Extracellular Enveloped Virus in the in vitro and in vivo Dissemination of Vaccinia,”J Gen Virol, vol. 50, pp. 89-100, 1980.
Sanderson et al., “Roles of vaccinia virus EEV-specific proteins in intracellular actin tail formation and low pH-induced cell-cell fusion”J Gen Virol, vol. 79, pp. 1415-1425, 1998.
Schmelz et al., “Assembly of Vaccinia Virus: the Second Wrapping Cisterna Is Derived from the Trans Golgi Network,”J Virol, vol. 68, pp. 130-147, 1994.
Schofield et al, “Four Chimpanzee Monoclonal Antibodies Isolated by Phage Display Neutralize Hepatitis A Virus,”Virology, vol. 292, pp. 127-136, 2002.
Smith et al, “Extracellular enveloped vaccinia virus. Entry, egress, and evasion,”Adv Exp Med Biol, vol. 440, pp. 395-414, 1998.
Vanderplasschen et al., “Intracellular and Extracellular vaccinia virions enter cells by different mechanisms,”J Gen Virol, vol. 79, pp. 877-887, 1998.
Wolffe et al., “Deletion of the Vaccinia Virus B5R Gene Encoding a 42-Kilodalton Membrane Glycoprotein Inhibits Extracellular Virus Envelope Formation and Dissemination,”J Virol, vol. 67, pp. 4732-4741, 1993.
Chen Zhaochun
Earl Patricia
Emerson Suzanne U.
Moss Bernard
Purcell Robert H.
Li Bao
Sheridan & Ross P.C.
The United States of America as represented by the Department of
LandOfFree
Monoclonal antibodies against orthopoxviruses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies against orthopoxviruses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies against orthopoxviruses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2631662